Home >> Industry News >> All The News
sideview vmo3D sideview vmo3D 30 day free trial
  • Also available via:

Visual rehabilitation faster after LASEK than after epi-LASIK PDF
Submit Your News
Ophthalmology and Optometry
Wednesday, 01 October 2008
A retrospective study suggests that visual rehabilitation in patients with low to moderate myopia may be faster, safer, more effective and more predictable after LASEK than after epi-LASIK with repositioning of the epithelial flap. However, visual and refractive outcomes for these patients appear similar at 3 postoperative months.

Miguel A. Teus, MD, PhD, and colleagues compared visual results for 47 eyes that were treated with LASEK with 47 age- and refraction-matched eyes that were treated with epi-LASIK. In all cases, the epithelial flap was replaced after ablation. Visual outcomes were compared between the surgical groups at 1 day, 1 week, and 1 and 3 months postop. Preoperative spherical manifest refraction was similar for both the LASEK and epi-LASIK groups, the authors noted.

At 1 day postop, uncorrected visual acuity averaged 0.7 in the LASEK group, significantly better than 0.5 in the epi-LASIK group (P < .001); however there was no significant difference in UCVA at 1 week, according to the study.

At 1 month postop, UCVA averaged 0.94 in the LASEK group, significantly better than 0.82 in the epi-LASIK group (P < .001); however, the investigators observed no significant difference in UCVA between the groups at 3 months.

At 3 months, 78.7% of eyes in the LASEK group and 65.9% of eyes in the epi-LASIK group had achieved UCVA of 1.0 or better.

Also at 3 months, safety (P = .04) and efficacy (P = .01) indices were significantly better after LASEK than after epi-LASIK, according to the study, published in the September issue of American Journal of Ophthalmology.
Novagali Pharma completes a €15 million fund raising PDF
Submit Your News
International News
Tuesday, 30 September 2008
Novagali Pharma, a French Laboratory specialized in ophthalmology announced it has secured €15 million in a new financing round with the participation of the historical Company investors.

Thanks to this new contribution Novagali Pharma will continue to develop its high potential projects:
  • The commercialization in France and abroad of its first marketable product, Cationorm®, indicated for the treatment of dry eye symptoms,
  • The development of its flagship products: Vekacia® (Vernal keratoconjunctivitis), Cyclokat® (Dry eye), Nova21027 (Glaucoma) and Cortiject® (Diabetic macular edema), and particularly for Cyclokat® the phase III clinical study now in course in Europe and the one initiated in the United States during the third quarter of 2008 as well as the phase I finalization in patient with Cortiject® started in April 2008 in the United States.
Three more videos added from Hoya Australia PDF
Submit Your News
Product News
Tuesday, 30 September 2008
Three more videos from Hoya Australia have been added to EYESMART TV. The videos are about: Hoyalux FD, Hoya Individual Free Form Lens D, and Hoya ID Lens.
Person unable to open eyes 3 days a week! PDF
Submit Your News
Australian News
Tuesday, 30 September 2008
An Australian woman is blind three days out of every six because her eyes involuntarily shut and she cannot open them, a report has said. The woman's mysterious medical condition has left doctors puzzled.

Natalie Adler, who experts believe may be the only person in the world with this condition, said she has had this medical predicament since she was 17.

Doctors from the Royal Victoria Eye and Ear Hospital said Ms Adler's condition was baffling. Professor O'Day said the medical condition blepharospasm, which causes an involuntary closing of the eyes, could be used as a reference but that it did not explain why Ms Adler's eyes closed according to a routine.
Discontinuation of BETAGAN® (levobunolol hydrochloride) PDF
Submit Your News
Product News
Monday, 29 September 2008
Further to their communication of 27 May 2008, Allergan Australia Pty Ltd regret to inform that, despite lengthy discussions with the TGA, Allergan have been unable to resolve the manufacturing specification issue. As a result, effective immediately (September 2008) the supply of BETAGAN® (levobunolol hydrochloride) 2.5 mg/mL Eye Drops 5mL will be discontinued.
<< Start < Prev 221 222 223 224 225 226 227 228 229 230 Next > End >>

Page 226 of 297